Sirtuin proteins regulate diverse cellular pathways that influence genomic stability, metabolism and ageing 1,2 . SIRT7 is a mammalian sirtuin whose biochemical activity, molecular targets and physiological functions have been unclear. Here we show that SIRT7 is an NAD 1 -dependent H3K18Ac (acetylated lysine 18 of histone H3) deacetylase that stabilizes the transformed state of cancer cells. Genome-wide binding studies reveal that SIRT7 binds to promoters of a specific set of gene targets, where it deacetylates H3K18Ac and promotes transcriptional repression. The spectrum of SIRT7 target genes is defined in part by its interaction with the cancer-associated E26 transformed specific (ETS) transcription factor ELK4, and comprises numerous genes with links to tumour suppression. Notably, selective hypoacetylation of H3K18Ac has been linked to oncogenic transformation, and in patients is associated with aggressive tumour phenotypes and poor prognosis 3-6 . We find that deacetylation of H3K18Ac by SIRT7 is necessary for maintaining essential features of human cancer cells, including anchorageindependent growth and escape from contact inhibition. Moreover, SIRT7 is necessary for a global hypoacetylation of H3K18Ac associated with cellular transformation by the viral oncoprotein E1A. Finally, SIRT7 depletion markedly reduces the tumorigenicity of human cancer cell xenografts in mice. Together, our work establishes SIRT7 as a highly selective H3K18Ac deacetylase and demonstrates a pivotal role for SIRT7 in chromatin regulation, cellular transformation programs and tumour formation in vivo.
Sirtuin proteins regulate diverse cellular pathways that influence genomic stability, metabolism and ageing 1, 2 . SIRT7 is a mammalian sirtuin whose biochemical activity, molecular targets and physiological functions have been unclear. Here we show that SIRT7 is an NAD 1 -dependent H3K18Ac (acetylated lysine 18 of histone H3) deacetylase that stabilizes the transformed state of cancer cells. Genome-wide binding studies reveal that SIRT7 binds to promoters of a specific set of gene targets, where it deacetylates H3K18Ac and promotes transcriptional repression. The spectrum of SIRT7 target genes is defined in part by its interaction with the cancer-associated E26 transformed specific (ETS) transcription factor ELK4, and comprises numerous genes with links to tumour suppression. Notably, selective hypoacetylation of H3K18Ac has been linked to oncogenic transformation, and in patients is associated with aggressive tumour phenotypes and poor prognosis [3] [4] [5] [6] . We find that deacetylation of H3K18Ac by SIRT7 is necessary for maintaining essential features of human cancer cells, including anchorageindependent growth and escape from contact inhibition. Moreover, SIRT7 is necessary for a global hypoacetylation of H3K18Ac associated with cellular transformation by the viral oncoprotein E1A. Finally, SIRT7 depletion markedly reduces the tumorigenicity of human cancer cell xenografts in mice. Together, our work establishes SIRT7 as a highly selective H3K18Ac deacetylase and demonstrates a pivotal role for SIRT7 in chromatin regulation, cellular transformation programs and tumour formation in vivo.
The chromatin silencing factor Sir2 (silent information regulator-2) catalyses NAD 1 -dependent histone deacetylation to regulate genomic stability and cellular senescence in budding yeast 1, 2 . In mammals, SIRT7 is the only sirtuin (Sir2 family member) for which a clear enzymatic activity has remained elusive. Indirect evidence has led to the suggestion that SIRT7 deacetylates the tumour suppressor p53 (ref. 7) , although in vitro and cellular data do not support this model ( Supplementary Fig. 1 and ref. 8 ). In addition, multiple studies have failed to detect direct deacetylase activity of SIRT7 on histones or other substrates 1 .
In biochemical fractionation studies, we detected SIRT7 almost exclusively in a chromatin-enriched fraction, suggesting that SIRT7 might function at chromatin ( Fig. 1a ). We therefore used mass spectrometry to screen for potential NAD 1 -dependent histone deacetylase activity of SIRT7 in vitro. Notably, SIRT7 showed highly specific deacetylase activity on peptides containing H3K18Ac, but had no activity on 12 other histone acetylation sites tested (Fig. 1b, c) . This striking selectivity of SIRT7 for H3K18Ac contrasts with the broader substrate spectrum of other deacetylases such as SIRT1 (Supplementary Table 1 ) or HDAC1 (ref. 9). SIRT7 also showed robust and specific NAD 1 -dependent H3K18Ac-deacetylase activity on full-length histone H3 in purified poly-nucleosomes ( Fig. 1d ). This activity was abolished by substitution of a conserved histidine residue (H187RY) in the predicted catalytic domain of SIRT7 and by the general sirtuin inhibitor nicotinamide ( Fig. 1e ). Selective H3K18Ac deacetylation was also observed in cells after overexpression of the wild-type, but not mutant, SIRT7 protein ( Fig. 1f ). Moreover, an unbiased proteomic approach using quantitative mass spectrometry independently demonstrated that SIRT7 overexpression induces a dramatic depletion of H3K18Ac in cells ( Fig. 1g ), whereas changes in other acetylation marks, presumably caused by downstream effects on chromatin structure, were more modest or negligible. Together, our data demonstrate that SIRT7 is an NAD 1 -dependent H3K18Ac deacetylase and the first known deacetylase with high selectivity for the H3K18Ac chromatin mark.
Depletion of H3K18Ac has been associated with aggressive cancer phenotypes and poor patient prognosis 5, 6 , and in cellular studies has been linked to epigenetic reprogramming during transformation of primary human cells by viral oncoproteins 3, 4 . In addition, H3K18Ac is enriched at gene promoters and correlates with transcriptional activation 10 . We therefore hypothesized that SIRT7 might deacetylate H3K18Ac at promoters to modulate cancer-related gene expression programs. We first determined the genome-wide occupancy of SIRT7 by chromatin immunoprecipitation (ChIP) sequencing. Results from multiple independent ChIP-sequencing experiments identified 276 SIRT7-binding sites ( Supplementary Tables 2-4 ), which were dramatically enriched for proximal promoter regions ( Fig. 2a, b and Supplementary Fig. 2a, b ). Notably, SIRT7-binding sites also overlapped significantly with previously mapped regions of H3K18Ac enrichment (P , 1.4 310 280 ) (ref. 10). Together, these data suggest that SIRT7 is a locus-specific enzyme that is positioned to deacetylate H3K18Ac at promoters of a select set of gene targets.
The identified SIRT7 ChIP-sequencing peaks correspond to 241 protein-coding genes (see Methods for details). Using ChIPquantitative PCR (qPCR) we confirmed the binding of SIRT7 at several of the identified promoters and validated the specificity of the ChIP signals by short interfering RNA (siRNA)-mediated depletion of SIRT7 ( Fig. 2c and Supplementary Fig. 3 ). Functional categorization of the SIRT7-bound genes revealed strong enrichment for factors involved in RNA processing, protein translation and cellular macromolecule metabolism, with diverse links to tumour suppressive activities ( Supplementary Fig. 2 ). Interestingly, SIRT7 bound upstream of several ribosomal protein (RP) genes, whose mis-regulation has 
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been linked to cancer in multiple settings (see below), as well as genes found repressed in aggressive cancers or identified in screens for tumour suppressor genes (for example, NME1 and COPS2) 11, 12 .
We next asked whether SIRT7 deacetylates H3K18Ac at the promoters of specific candidate target genes. SIRT7 depletion led to hyperacetylation of H3K18 at the promoters of the RPS20, RPS7, RPS14, NME1 and COPS2 genes, but not multiple negative control promoters ( Fig. 2d and Supplementary Fig. 4 ). Consistent with this locus specificity, global H3K18Ac levels were not affected by SIRT7 depletion (Supplementary Fig. 5 ). Importantly, SIRT7 knockdown (S7KD) also led to specific increases in expression of multiple target genes (Fig. 2e, f and Supplementary Figs 6 and 7) , whereas depletion of HDAC1 (which can also deacetylate H3K18Ac 9 ) did not (Supplementary Fig. 8 ). Together, our findings demonstrate that SIRT7 functions in gene-specific transcriptional repression at a select subset of H3K18Ac-containing promoters.
We next asked how selective recruitment of SIRT7 to its target promoters is achieved. SIRT7 lacks known sequence-specific DNAbinding domains, leading us to hypothesize that it might interact with other proteins that contain such domains. We therefore identified de novo DNA motifs that are enriched in SIRT7-bound promoter sequences, and compared these motifs with curated transcriptionfactor binding motifs in the JASPAR CORE database 13 . Of the 50 most significant SIRT7-associated motifs, 25 corresponded to consensusbinding sites for the ETS family of transcription factors, many of which are important modulators of cellular transformation and cancer progression 14 . The SIRT7 consensus motif was most similar to the DNA sequence recognized by the ETS protein ELK4 (Fig. 3a) .
Although its molecular function has not been extensively studied, ELK4 has been implicated in both transcriptional activation and repression 15 . Of the 276 SIRT7-binding sites that we identified by ChIP-sequencing, 57.6% contain at least one ELK4 consensus motif, a significant enrichment over total RefSeq promoters (P , 3.1 3 10 289 ) ( Supplementary Tables 5, 6 ). In addition, approximately 70% of SIRT7binding sites overlap with ELK4 peaks previously identified by ChIPsequencing (P , 1 3 10 2300 ) (ref. 16 ). To examine the potential interplay between SIRT7 and ELK4, we first confirmed that ELK4 binds several of the SIRT7 target promoters that contain the ETS consensus motif (NME1 and COPS2), but not promoters lacking the motif (RPS20 or GAPDH; Supplementary Fig. 9a ). Next, in coimmunoprecipitation experiments, we found that SIRT7 interacts physically with ELK4 (Fig. 3b, c and Supplementary Fig. 10a ), but not with two other ETS proteins, ELK1 and GABP-a (Supplementary Fig. 10b ). To assess the functional importance of this interaction, we examined the effects of ELK4 knockdown on SIRT7 ChIP occupancy at specific target promoters. Depletion of ELK4 led to a partial but significant decrease in SIRT7 occupancy at the NME1 and COPS2 promoters but not the RPS20 promoter (Fig. 3d, e and Supplementary Fig. 11a, b) , and did not alter global levels of SIRT7 at chromatin ( Supplementary Fig. 12 ). Moreover, ELK4 knockdown led to elevated H3K18Ac levels at the NME1 and COPS2 promoters, but not at promoters lacking the ETS motif ( Supplementary Fig. 9b ). Together, these findings suggest that ELK4 functions to target SIRT7 to specific promoters for H3K18 deacetylation.
We next examined the effects of ELK4 knockdown on gene repression by SIRT7. ELK4 knockdown did not appreciably alter expression of NME1 and COPS2 under baseline conditions (Fig. 3f ), probably because considerable SIRT7 protein remained bound at these promoters (Fig. 3e ). This incomplete loss of promoter-bound SIRT7 could reflect the incomplete depletion of ELK4 (Fig. 3d ) as well as compensatory activity of other ETS factors in SIRT7 targeting. Indeed, the SIRT7 ChIP-sequencing peaks displayed some overlap (25%; P , 1 3 10 2300 ) with binding sites for ELK1. Importantly, however, knockdown of ELK4, but not ELK1 or GABP-a, was sufficient to impair gene repression induced by overexpression of SIRT7 ( Fig. 3f and Supplementary  Figs 11c and 13) . Thus, any compensatory capacity of other ETS factors is exceeded under conditions of elevated SIRT7 expression, and in this setting ELK4 is the main ETS factor responsible for SIRT7 targeting. Thus, we conclude that the promoter stabilization of SIRT7 by ELK4 is important for SIRT7-mediated gene repression. Moreover, this functional interplay between ELK4 and SIRT7 might be particularly important in settings of elevated SIRT7 expression, which occurs in certain cancers ( Supplementary Fig. 14) [17] [18] [19] .
Analysis of SIRT7-occupied genes revealed a clear correlation with factors whose expression is altered in various cancers ( Supplementary  Fig. 2d ). This observation, together with previous reports linking both H3K18Ac 3-6 and ELK4 (ref. 20) to cancer, suggested that SIRT7 might regulate transformed features of cancer cells. Indeed, SIRT7 depletion in HT1080 and U2OS cells severely impaired both anchorageindependent cellular growth in soft agar and proliferation in low serum, two important hallmarks of transformed cells (Fig. 4a, b and Supplementary Figs 15 and 16) . These effects of SIRT7-depletion were associated with both increased cell death and altered cell-cycle progression ( Supplementary Fig. 17 ), and were observed in prostate cancer cells, a setting where overexpression of both ELK4 and SIRT7 
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has been observed ( Supplementary Fig. 14) 20 . Importantly, functional reconstitution assays revealed that the catalytic activity of SIRT7 is necessary for maintenance of the cancer cell-specific growth properties (Fig. 4a, b and Supplementary Fig. 16 ), linking the biochemical activity and cancer-related functions of SIRT7. In addition, simultaneous expression of SIRT7 and ELK4 had a synergistic effect on maintenance of the transformed phenotype of these cells ( Supplementary Fig. 18 ), further highlighting the importance of the molecular interplay between SIRT7 and ELK4. The adenoviral E1A oncoprotein induces a specific decrease in H3K18 acetylation that is important for its transforming activity 3, 4 . Strikingly, SIRT7 depletion in HT1080 cells severely inhibited this E1A-dependent reduction of H3K18Ac (Fig. 4c) . Moreover, expression of E1A in non-dividing, contact-inhibited primary human fibroblasts triggers cell-cycle re-entry and escape from contact inhibition, another hallmark of oncogenic transformation 21 , and SIRT7 depletion abolished this effect (Fig. 4d) . Thus, SIRT7 is required for both the global H3K18Ac deacetylation and escape from contact inhibition that are induced by the E1A oncoprotein. Finally, we examined the effect of SIRT7-knockdown on tumour growth using subcutaneous xenografts of U251 cancer cells in mice, and found that tumour formation was severely impaired by SIRT7 depletion (Fig. 4e, f and Supplementary  Fig. 19 ). Together, our data suggest that H3K18Ac-specific deacetylation by SIRT7 is important for maintaining fundamental properties of the cancer cell phenotype and stabilizing the tumorigenicity of human cancer cells in vivo.
In summary, we have demonstrated that SIRT7 is a promoterassociated, highly selective H3K18Ac deacetylase that mediates transcriptional repression and stabilizes cancer cell phenotypes. These findings suggest that pathological upregulation of SIRT7 in cancer cells may contribute to the malignant phenotype of certain tumours. Indeed, SIRT7 overexpression is observed in multiple cancer tissues ( Supplementary Fig. 14) [17] [18] [19] , and the cBio Cancer Genomics Portal has reported 55 separate instances of SIRT7 gene amplification in patients' tumours so far (http://www.cbioportal.org). We note that although SIRT7 is important for maintaining the transformed state of cancer cells, we have not observed a role for SIRT7 in initiating the process of cellular transformation itself. For example, overexpression of SIRT7 in immortalized mouse embryonic fibroblasts or primary human fibroblasts did not lead to oncogenic transformation (data not shown, and ref. 8). Thus, our data suggest models in which H3K18Ac deacetylation by SIRT7 modulates the epigenetic stability and tumorigenicity of cancer cells, but how SIRT7 deficiency impacts on tumour initiation and the overall incidence of cancer is probably more complex.
Our observation that SIRT7 represses several ribosomal protein genes is intriguing, as mutations in ribosomal protein genes have been linked to cancer progression 22, 23 . For example, the SIRT7 target gene RPS14 is a disease gene of the human 5q 2 syndrome, a myelodysplastic disorder that frequently progresses to acute myeloid leukaemia 23 , and multiple ribosomal proteins have been identified as haploinsufficient tumour suppressors in zebrafish 22 . The molecular mechanisms underlying the links between ribosomal protein insufficiency and cancer are 
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unclear, but have been hypothesized to involve imbalances in translation regulation or translation-independent functions of individual ribosomal proteins 22, 23 .
Previous studies have found that SIRT7 promotes ribosomal RNA transcription 24 , although this function appears to be specific to cell type or experimental conditions ( Supplementary Fig. 20 ). Whether such an activity functions in parallel to, or as a consequence of, SIRT7's role in ribosomal protein gene repression remains to be elucidated, but may suggest a broad role for SIRT7 in coordinating the cellular translation machinery. Interestingly, ribosomal protein gene deletions and inhibition of translation have also been linked to lifespan extension in numerous model organisms, including mammals 25, 26 , suggesting that gene repression by SIRT7 might also influence ageing-related cellular processes. Consistent with this hypothesis, one strain of Sirt7-deficient mice shows cardiac defects and shortened lifespan 8 , although this phenotype appears to depend on genetic background 27 . Future work should shed light on the potential role of SIRT7 in ageing-associated pathologies and lifespan determination.
METHODS SUMMARY
Histone deacetylation assays. In vitro histone deacetylation assays were performed as previously described 28 using acetylated peptides or poly-nucleosomes purified from HeLa cells as substrate. Recombinant human SIRT7 protein was purified from baculovirus-infected insect cells as described 8 . ChIP-qPCR and messenger RNA analysis. ChIP was performed as previously described 29 , except that the Qiagen PCR purification kit was used for DNA purification (Qiagen). Whole messenger RNA was purified from cells using the RNEasy Mini Kit (Qiagen). Quantitative reverse transcription PCR was performed using the Universal ProbeLibrary System with a LightCycler 480 II (Roche), or using Taqman Gene Expression Assays on a 7300 Real Time PCR machine (Applied Biosystems). RNA from patient-matched tumour and unaffected control tissues was purchased from Ambion. Tumour xenograft experiments. Equal numbers of U251 cells expressing luciferase and either control (pSR) or SIRT7 knockdown vectors (upper quadrants, 4 3 10 6 pSR or S7KD1 cells; lower quadrants, 8 3 10 6 pSR or S7KD2 cells) were implanted on the backs of RAG knockout mice. Tumour growth was monitored using callipers and visualized with a bioluminescence-based IVIS system (Caliper LifeSciences).
